Vor Biopharma Inc. VOR
19.03 USD -0.39 (-2.01%)
As ofNov 16, 2026, 3:47 PM EST
19.01 Day range 20.29
6.50 52-week range 26.00
- YTD
- +45.49%
- 1 year
- +90.11%
News
globenewswire.com Vor Bio Expands Strategic Partnership with RemeGen, Adding Next Generation, Long-Acting RC298 to BAFF/APRIL Franchise RemeGen's expertise and next generation engineering expand Vor Bio's leadership in the BAFF/APRIL field RC298 is a next generation, long-acting dual BAFF/APRIL inhibitor designed to combine high…
globenewswire.com Vor Bio To Participate in 2026 Jefferies Global Healthcare Conference BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will…benzinga.com Vor Bio Announces Final Two-Year Results From Phase 3 TELIGAN Trial Evaluating Telitacicept In Adults With Iga Nephropathy; TELIGAN Met Stage B Primary Endpoint Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001)89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines,
